[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
IJRR Information::
For Authors::
For Reviewers::
News & Events::
Web Mail::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Hard Copy 2322-3243
Online 2345-4229
Online Submission
Now you can send your articles to IJRR office using the article submission system.



:: Volume 22, Issue 2 (4-2024) ::
Int J Radiat Res 2024, 22(2): 397-403 Back to browse issues page
Estrogen receptor ER-α36: A diagnostic biomarker for endometrial cancer
F. Li , L. Li , H. Li
The Fourth Hospital of Shijiazhuang, Shijiazhuang, Hebei, 050000, China , 13472192605@163.com
Abstract:   (110 Views)
Background: In this experiment, we intend to investigate the relationship between ER-α36 expression and endometrial cancer. Materials and Method: A total of 172 healthy control and endometriosis patients were selected from our hospital. These included 43 cases of normal endometrium (NE group), 43 cases of endometrium without atypical hyperplasia (EH group), 43 cases of atypical hyperplasia (AH group) and 43 cases of endometrial cancer (EC group). The expression of ER-α36 in these tissues was detected by immunohistochemical methods. Results: The positive rate of estrogen receptor (ER-α36) in each group was 4.24%±5.02%, 5.74%±6.34%, 9.69%±9.42%, and 11.78%±10.39%, respectively. The expression of ER-α36 demonstrated a notably higher level in the AH and EC groups compared to the EH and NE groups. A statistically significant difference was observed between the NE group and the AH group (P=0.0112). The NE group was statistically different from the EC group (P=0.0001).There was a statistical difference between the EH group and the EC group (P=0.0040). Among endometrial cancers, the mean positive rate of ER-α36 expression was 11.67%±6.74% in highly differentiated endometrial cancers, 9.45%±11.38% in moderately differentiated, and 14.82%±11.35% in poorly differentiated. Comparison between the two groups showed that there was no statistically significant difference in the expression positivity rate of ER-α36 in endometrial cancer of different degrees of differentiation (P>0.05). Conclusion: ER-α36 has a certain diagnostic efficacy for endometrial cancer and can be used as an auxiliary judgment tool for pathological examination.
Keywords: ER-α36, diagnosis, endometrium cancer.
Full-Text [PDF 741 kb]   (25 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Li F, Li L, Li H. Estrogen receptor ER-α36: A diagnostic biomarker for endometrial cancer. Int J Radiat Res 2024; 22 (2) :397-403
URL: http://ijrr.com/article-1-5448-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 22, Issue 2 (4-2024) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 50 queries by YEKTAWEB 4652